Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background In the treatment of type 2 diabetes, GLP-1 receptor agonists lower blood glucose concentrations, body weight, and have cardiovascular benefits. The efficacy and side effects of GLP-1 receptor agonists vary between people. Human pharmacogenomic studies of this inter-individual variation can provide both biological insight into drug action and provide biomarkers to inform clinical decision making. We therefore aimed to identify genetic variants associated with glycaemic response to GLP-1 receptor agonist treatment. Methods In this genome-wide analysis we included adults (aged ≥18 years) with type 2 diabetes treated with GLP-1 receptor agonists with baseline HbA 1c of 7% or more (53 mmol/mol) from four prospective observational cohorts (DIRECT, PRIBA, PROMASTER, and GoDARTS) and two randomised clinical trials (HARMONY phase 3 and AWARD). The primary endpoint was HbA 1c reduction at 6 months after starting GLP-1 receptor agonists. We evaluated variants in GLP1R , then did a genome-wide association study and gene-based burden tests. Findings 4571 adults were included in our analysis, of these, 3339 (73%) were White European, 449 (10%) Hispanic, 312 (7%) American Indian or Alaskan Native, and 471 (10%) were other, and around 2140 (47%) of the participants were women. Variation in HbA 1c reduction with GLP-1 receptor agonists treatment was associated with rs6923761G→A (Gly168Ser) in the GLP1R (0·08% [95% CI 0·04–0·12] or 0·9 mmol/mol lower reduction in HbA 1c per serine, p=6·0 × 10 −5 ) and low frequency variants in ARRB1 (optimal sequence kernel association test p=6·7 × 10 −8 ), largely driven by rs140226575G→A (Thr370Met; 0·25% [SE 0·06] or 2·7 mmol/mol [SE 0·7] greater HbA 1c reduction per methionine, p=5·2 × 10 −6 ). A similar effect size for the ARRB1 Thr370Met was seen in Hispanic and American Indian or Alaska Native populations who have a higher frequency of this variant (6–11%) than in White European populations. Combining these two genes identified 4% of the population who had a 30% greater reduction in HbA 1c than the 9% of the population with the worse response. Interpretation This genome-wide pharmacogenomic study of GLP-1 receptor agonists provides novel biological and clinical insights. Clinically, when genotype is routinely available at the point of prescribing, individuals with ARRB1 variants might benefit from earlier initiation of GLP-1 receptor agonists. Funding Innovative Medicines Initiative and the Wellcome Trust
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434
Self-citationThe GTEx Consortium atlas of genetic regulatory effects across human tissues
The GTEx Consortium, Aguet, F., Anand, S., Ardlie, K. G., Gabriel, S., Getz, G. A., Graubert, A., Hadley, K., Handsaker, R. E., Huang, K. H., et al. (2020) · Science · doi:10.1126/science.aaz1776 · Cited by 5,547
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Cunningham, F., Allen, J. E., Allen, J., Alvarez-Jarreta, J., Amode, M. R., Armean, I. M., Austine-Orimoloye, O., Azov, A. G., Barnes, I., Bennett, R., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1049 · Cited by 1,923
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Self-citationSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
The Genotype-Tissue Expression (GTEx) Project
Carithers, L. J., & Moore, H. M. (2015) · Biopreservation and Biobanking · doi:10.1089/bio.2015.29031.hmm · Cited by 549
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 1×
“27,28 Our human pharmacogenetic studies resolve much of this uncertainty as they show convincingly that βarrestin1 clearly has a role in glycaemic response to GLP1 receptor agonists, but not weight response to GLP1 receptor agonists pointing to a likely βcell mechanism.”
Cited by
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Stefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00318-8 · Cited by 392
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Metadata
- Authors
- Dawed, A. Y., Mari, A., Brown, A., McDonald, T. J., Li, L., Wang, S., Hong, M.-G., Sharma, S., Robertson, N. R., Mahajan, A., Wang, X., Walker, M., Gough, S., Hart, L. M. ‘., Zhou, K., Forgie, I., Ruetten, H., Pavo, I., Bhatnagar, P., Jones, A. G., Pearson, E. R., 't Hart, L. M., Abdalla, M., Adam, J., Adamski, J., Adragni, K., Allin, K. H., Arumugam, M., Atabaki Pasdar, N., Baltauss, T., Banasik, K. B., Baum, P., Bell, J. D., Bergstrom, M., Beulens, J. W., Bianzano, S., Bizzotto, R., Bonneford, A., Brorsson, C. A. B., Brown, A. A., Brunak, S. B., Cabrelli, L., Caiazzo, R., Canouil, M., Dale, M., Davtian, D., Dawed, A. Y., De Masi, F. M., de Preville, N., Dekkers, K. F., Dermitzakis, E. T., Deshmukh, H. A., Dings, C., Donnelly, L., Dutta, A., Ehrhardt, B., Elders, P. J. M., Engel Thomas, C. E. T., Engelbrechtsen, L., Eriksen, R. G., Eriksen, R. E., Fan, Y., Fernandez, J., Ferrer, J., Fitipaldi, H., Forgie, I. M., Forman, A., Franks, P. W., Frau, F., Fritsche, A., Froguel, P., Frost, G., Gassenhuber, J., Giordano, G. N., Giorgino, T., Gough, S., Graefe-Mody, U., Grallert, H., Grempler, R., Groeneveld, L., Groop, L., Gudmundsdóttir, V. G., Gupta, R. G., Haid, M., Hansen, T., Hansen, T. H., Hattersley, A. T., Haussler, R. S., Heggie, A. J., Hennige, A. M., Hill, A. V., Holl, R. W., Hong, M.-G., Hudson, M., Jablonka, B., Jennison, C., Jiao, J., Johansen, J. J., Jones, A. G., Jonsson, A., Karaderi, T. K., Kaye, J., Klintenberg, M., Koivula, R. W., Kokkola, T., Koopman, A. D. M., Kurbasic, A., Kuulasmaa, T., Laakso, M., Lehr, T., Loftus, H., Lundbye Allesøe, R. L. A., Mahajan, A., Mari, A., Mazzoni, G. M., McCarthy, M. I., McDonald, T. J., McEvoy, D., McRobert, N., McVittie, I., Mourby, M., Musholt, P., Mutie, P., Nice, R., Nicolay, C., Nielsen, A. M. N., Nilsson, B. N., Palmer, C. N., Pattou, F., Pavo, I., Pearson, E. R., Pedersen, O., Pedersen, H. K. P., Perry, M. H., Pomares-Millan, H., Ramisch, A., Rasmussen, S. R., Raverdi, V., Ridderstrale, M., Robertson, N., Roderick, R. C., Rodriquez, M., Ruetten, H., Rutters, F., Sackett, W., Scherer, N., Schwenk, J. M., Shah, N., Sharma, S., Sihinevich, I., Sondertoft, N. B., Staerfeldt, H., Steckel-Hamann, B., Teare, H., Thomas, M. K., Thomas, E. L., Thomsen, H. S., Thorand, B., Thorne, C. E., Tillner, J., Troen Lundgaard, A. T. L., Troll, M., Tsirigos, K. D. T., Tura, A., Uhlen, M., van Leeuwen, N., van Oort, S., Verkindt, H., Vestergaard, H., Viñuela, A., Vogt, J. K., Wad Sackett, P. W. S., Wake, D., Walker, M., Wesolowska-Andersen, A., Whitcher, B., White, M. W., & Wu, H.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 11
- Issue
- 1
- Pages
- 33-41
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W4312019552
- Cited by
- 131
- References
- 14
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. https://app.cochat.ai/papers/10.1016/s2213-8587(22)00340-0
- The paper
- Dawed, A. Y., Mari, A., Brown, A., McDonald, T. J., Li, L., Wang, S., Hong, M.-G., Sharma, S., Robertson, N. R., Mahajan, A., Wang, X., Walker, M., Gough, S., Hart, L. M. ‘., Zhou, K., Forgie, I., Ruetten, H., Pavo, I., Bhatnagar, P., . . . Wu, H. (2023). Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(22)00340-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.